aTyr Pharma (ATYR) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$10.3M

Net income growth (year over year)

+47.21%

Net margin

—

Return on equity

−98.37%

EPS (trailing twelve months)

−$0.63

Book value per share

$0.50

P/E (trailing twelve months)

—

Price to book

0.41

Debt to assets

30.41%

Payout ratio

—

Dividend yield

—

Company profile

aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).

• How do I buy stock in aTyr Pharma (ATYR)?

  ATYR trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.